At the Heart of a First R01 Grant

At the Heart of a First R01 Grant 150 150 Alaina Doklovic

Allison Bradbury, MS, PhD, is a principal investigator in the Center for Gene Therapy at Nationwide Children’s Hospital and an assistant professor in the Department of Pediatrics at The Ohio State University. She recently received her first R01 grant to develop novel therapeutic strategies for tubulin folding cofactor D (TBCD)-related developmental and epileptic encephalopathy. This is a multi-PI R01 with Mark Hester, PhD, a principal investigator in the Institute of Genomic Medicine. Rolf Stottmann, PhD; Meisam Kararoudi, DVM, PhD; and Margie Ream, MD, PhD are co-investigators.

The heartwarming story of this grant started two years ago, when Dr. Bradbury connected with a six-year-old named Landon from Columbus. Landon has an ultrarare genetic disorder involving a TBCD mutation. Since no disease models existed for his condition, Dr. Bradbury and her team sought to develop a gene therapy for TBCD.

Dr. Bradbury’s connection with Landon and her work on his disease have been featured in the news and through an article by The Ohio State University. This six-year-old boy, and the approximately 40 other known cases of this disorder worldwide, are at the heart of her R01 Grant. Dr. Bradbury is one of only a few researchers actively researching gene therapy for this rare disorder.

About the author

Alaina Doklovic is a Marketing Specialist for Research Communications at Nationwide Children’s Hospital. She received her BS in medical anthropology and English from The Ohio State University. Her passions for science and health, combined with her desire to help others, motivated her to pursue a career in which she could actively help improve patient outcomes and scientific research through writing.